Genmab — Marts 2016
-
Genmab Provides Update on Ofatumumab Development in Autoimmune Indications - http://ir.genmab.com/releasedetail.cfm?ReleaseID=959265
-
og så vi andre kan læse den https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=283680007&sourcecode=omxnews
-
Den slags udsving giver bare os langsigtede en købsmulighed. Ingen grund til at sige øv om det.
-
Og nye investorer kan så også benytte lejligheden til køb.
-
Det er straks værre vis nyhedsstrømmen som forårsager fald skyldes noget selskabsspecifikt.
-
Celsius - hvorfor skal vi så
meget ned. DAX p.t. - 0,8%. NBI pænt i + i går -
3-4% lyder voldsom.
-
Dean - det er Novartis der er Partner i Ofa. Focus fra Novartis vil være på Ofa i Mutiple Sclerose
-
For dem der har interesse for teknik, så betyder luk under 810 vist nok, at den påbegyndte opadgående trend er brudt.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind